Arthneeti
Latest: Epigral Ltd Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
E

Epigral Ltd

Q1 FY27

Epigral Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹996
Market cap₹4.3K Cr
P/E15.8
Updated16 Oct 2026
Read4 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
FundraiseFundraise planned

The short version

Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years. Epigral targets a compound annual growth rate (CAGR) of 15% to 20% for both top-line and bottom-line over the next 3 to 5 years, driven by ramp-up of new capacities and growing market demand.

From Epigral Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Good growth
  • Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years.
  • Growth driven by ramping up existing capacities (chlorotoluenes, caustic soda, CPVC) and commissioning new capacities such as Epoxy Resin, Epichlorohydrin (ECH), and multipurpose plants.
  • The company aims to expand from approximately INR2,500 crores current revenue to around INR3,000-3,500 crores in the near term, and with all plants at optimal utilization, the top line could reach INR4,000+ crores over time.
  • Domestic demand, especially in infrastructure, renewable energy, automotive, and pharmaceutical/agrochemical intermediates, is expected to sustain double-digit volume growth.

2 more points from Epigral Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Epigral Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Epigral Limited has approved a strategic capex plan for two new projects:
  • Epoxy Resin & Formulations plant with 125,000 tons per annum capacity.
  • A Multipurpose Plant (MPP) to manufacture downstream products of epichlorohydrin and chlorotoluenes value chain.
  • Total capex in chlorotoluenes around INR 250 crores has been done.
  • Combined peak revenue expected post these projects is INR 1,300 to 1,500 crores.
  • Overall capex including the MPP is expected to result in consolidated top line in the range of INR 700 to 800 crores initially.
  • Capex split: 40% internal accruals, 60% debt.
  • Estimated EBITDA margin for chlorotoluenes/MPP around 22%-23%.

2 more points from Epigral Ltd's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Related insights include: - The company is progressing with capacity expansion projects for Epichlorohydrin and CPVC resin as per timeline and budget. - There is an expected double-digit CAGR demand growth for these products over coming years. - Epigral is actively diversifying products, indicating a healthy demand pipeline.

2 more points from Epigral Ltd's call on order book

Create a free account to keep reading this call

Epigral Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Epigral's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Alufluoride (Q1 FY27)

    Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr

  • POCL Enterprises (Q1 FY27)

    466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto

  • Devson Catalyst (Q1 FY27)

    FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee

  • Ambani Orgochem (Q1 FY27)

    Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks

Compare:vs Solar Industriesvs Pidilite Industriesvs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Epigral Ltd Q1 FY27 results?

Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years. Epigral targets a compound annual growth rate (CAGR) of 15% to 20% for both top-line and bottom-line over the next 3 to 5 years, driven by ramp-up of new capacities and growing market demand.

What is Epigral Ltd share price analysis?

Epigral Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 15.8 with a market cap of ₹4,296 Cr. Investors should review the full earnings analysis for detailed insights.

Is Epigral Ltd planning capital expenditure?

Epigral Limited has approved a strategic capex plan for two new projects: - Epoxy Resin & Formulations plant with 125,000 tons per annum capacity.

Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.